Clinical Trial Update: A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating hypofractionated radiotherapy for limited metastatic non-small cell lung cancer with EGFR-sensitizing mutations after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: First People's Hospital of Hangzhou | Conditions: Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN